Compositions containing quaternary compounds in which the nitrogen atom is substituted by at least one alkyl group having at least 12 carbon atoms, and the composition includes at least 20% in weight by weight of the total composition, of ammonium halides in which the nitrogen atom is substituted by at least one alkyl group having at least 14 carbon atoms and more than 5%, preferably more than 7% in weight by weight of the total composition, of ammonium halides in which the nitrogen atom is substituted by at least one alkyl group having at least 16 carbon atoms. Also, ophthalmic oil-in-water emulsions containing such compositions, the ophthalmic emulsions being useful for eye care or for the treatment of eye conditions.

A composition including a poloxamer gel, wherein the poloxamer gel is a combination of poloxamer 407 and poloxamer 188, wherein the composition further include preserved water and wherein the composition does not contain pharmaceutical agents and radioactive compounds. A composition including a poloxamer gel, wherein the poloxamer gel is a combination of poloxamer 407 and poloxamer 188; wherein the composition further includes preserved water; wherein the composition is formed from poloxamer gel components having a mean size of at most 0.5 mm; and wherein the composition is a gel at temperatures ranging from 25.5° C. to 28.9° C. and a solid at temperatures ranging from 30° C. to 36° C.

The invention provides the use of a formulation containing cyclodextrine, quercetin and zinc, at appropriate concentrations to mitigate infections by enveloped viruses like SARS-CoV-2, influenza and HIV/AIDS, when administered via pulmonary and dermal route. While the different forms of cyclodextrin prevent the entry of coated virus into host cells by extracting and sequestering cholesterol molecules at the virus coat and at the host cell plasma membrane, the natural plant-based ionophore quercetin in the formulation, enables cellular entry of zinc, inhibiting viral replication by altering polymerase activity in the host cell. Hence cyclodextrine, and quercetin plus zinc, either in combination or in tandem order of administration, serves both as prophylactic and therapeutic.

A cosmetic composition for treating acne includes at least one acne treatment active, for example, salicylic acid or a derivative thereof, which may present in an amount that is greater than 1%, by weight, based on the weight of the sulfate-free cleansing composition, and an aqueous carrier that includes at least one surfactant selected from the group consisting of sarcosinates, betaines, and combinations thereof, at least one solubilizer comprising a polyethylene glycol compound, and water. When the sulfate-free cleansing composition is applied to a keratinous tissue it demonstrates deposition and retention of the beta hydroxy acid on the keratinous tissue after rinsing with water.

A method of treatment is disclosed, comprising administering a composition of Cyclodextrin and reduced, nanonized L-Glutathione to a patient in need of treatment, wherein the L-Glutathione molecule is non-acetylated, non-Esterified, and non-fatty acid attached.

The present invention generally relates to the field of skin care. More particularly, the invention relates to a cosmetic or therapeutic skin care composition comprising live bacteria of at least one Cutibacterium acnes (C. acnes) strain in combination with an antioxidant that specifically supports their viability during storage and/or their ability to replicate after application to the skin. Preferably, the cosmetic or therapeutic skin care composition comprises bacteria of at least one C. acnes strain selected from the group consisting of D1, A5, C1, C3, H1, H2,H3, K1,K2, K4, K6, K8, K9, L1, and F4. The invention also provides a method for treating or preventing acne by applying the skin care composition of the invention to a skin area in need of treatment. The invention also relates to the use of a skin care composition of the invention for treating or preventing acne.

Soluble drug delivery films can exhibit an enhanced stability.

Disclosed are pharmaceutical compositions comprising the peptide of SEQ ID No. 1, or a pharmaceutically acceptable salt or counterion thereof, methods of preparing such pharmaceutical compositions, and methods of treating diabetes and diabetes-related disorders with such pharmaceutical compositions.

Particles, compositions, and methods that aid particle transport in mucus are provided. The particles, compositions, and methods may be used, in some instances, for ophthalmic and/or other applications. In some embodiments, the compositions and methods may involve modifying the surface coatings of particles, such as particles of pharmaceutical agents that have a low aqueous solubility. Such compositions and methods can be used to achieve efficient transport of particles of pharmaceutical agents though mucus barriers in the body for a wide spectrum of applications, including drug delivery, imaging, and diagnostic applications. In certain embodiments, a pharmaceutical composition including such particles is well-suited for ophthalmic applications, and may be used for delivering pharmaceutical agents to the front of the eye and/or the back of the eye.

The present disclosure encompasses pharmaceutical composition, kits and methods for enhancing therapeutic compliance.